DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 6,490 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total transaction of $389,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Andrew K. Balo also recently made the following trade(s):

  • On Monday, September 11th, Andrew K. Balo sold 3,244 shares of DexCom stock. The stock was sold at an average price of $72.27, for a total transaction of $234,443.88.

DexCom, Inc. (DXCM) traded down $0.41 during trading on Friday, hitting $58.02. 1,860,000 shares of the stock were exchanged, compared to its average volume of 1,730,000. DexCom, Inc. has a 1 year low of $42.62 and a 1 year high of $88.80. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.

A number of brokerages have issued reports on DXCM. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $78.00 price objective (down from $87.00) on shares of DexCom in a research report on Wednesday, August 16th. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price objective (down from $85.00) on shares of DexCom in a research report on Thursday, September 28th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $62.00 price objective (down from $90.00) on shares of DexCom in a research report on Thursday, September 28th. Northland Securities downgraded shares of DexCom from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $85.00 to $60.00 in a research report on Thursday, September 28th. Finally, J P Morgan Chase & Co downgraded shares of DexCom from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $93.00 to $71.00 in a research report on Thursday, September 28th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $70.69.

Institutional investors have recently added to or reduced their stakes in the company. Winslow Capital Management LLC bought a new position in shares of DexCom during the 2nd quarter valued at approximately $117,451,000. State Street Corp lifted its stake in shares of DexCom by 2.5% during the 2nd quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock valued at $113,374,000 after buying an additional 37,581 shares in the last quarter. Peregrine Capital Management LLC lifted its stake in shares of DexCom by 24.5% during the 3rd quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock valued at $19,348,000 after buying an additional 77,868 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in shares of DexCom by 111.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,471 shares of the medical device company’s stock valued at $693,000 after buying an additional 4,995 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its stake in shares of DexCom by 67.2% during the 2nd quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock valued at $17,746,000 after buying an additional 97,479 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/02/dexcom-inc-dxcm-evp-andrew-k-balo-sells-6490-shares.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.